Biomarker and testing questions

Ask whether PD-L1 testing, tumor type, prior treatment, or combination therapy affects eligibility.

Second-opinion questions

What test results make this treatment appropriate, and what are the alternatives if biomarkers are negative or unclear?

Safety discussion reminder

Immune-related side effects require prompt reporting and clinician guidance.

Official source links